Saturday 17 October 2026 Export ACRS’s income statement to Excel — free account

Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $7.8 million, down 58.2% from fiscal 2024. In the quarter to June 2026, revenue fell 8.33%, EPS fell 15.4% and free cash flow fell 98.8%, each against the same quarter a year earlier.

3.28 0.21 −6.02%

Follow ACRS

Alert me

Market cap: $513.7M
P/E: 0.0×
Fwd P/E: −6.7×
Dividend yield: —
F-score: 3/9
Altman Z: −5.60
Beneish M: −2.97
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 1.36

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	1	—	—	—	—	—	—

Insider Ownership 22.19%

Capital & Financial Ratios $m

Market Cap 513.72

Revenue 8.22

Net Income (75.74)

Free Cash Flow (62.18)

Net Debt (91.56)

Current Ratio 3.46

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (6.72)

P/S ratio 56.96

P/B ratio 3.76

Past 5Y EPS Growth —

This Y EPS Growth (25.43%)

Next Y EPS Growth (14.21%)

Next Y revenue growth (19.01%)

Next 5Y EPS Growth (14.22%)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 68.59%

10-year low 10-year high

P/B against its own 10 years 61.26%

10-year low 10-year high

EV/Sales against its own 10 years 62.36%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	119	114	91	92
Receivables	0	12	6	6
Inventory	—	—	—	—
Other	—	—	—	—
	129	126	96	98

	2023	2024	2025	Q'26
Payables	9	5	13	16
ST’ Debt	—	—	—	—
Other	3	3	3	—
	31	32	29	28

Compound Annual Growth %

	10y	5y	3y
Sales	—	3.84%	(35.93%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	1.09%	22.32%	(19.50%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	2	2	—	—	—
’25	1	2	3	1	8
’24	2	3	4	9	19
’23	3	2	9	18	31
’22	1	2	19	8	30
’21	2	2	2	2	7
’20	1	2	1	2	6

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(18)	(20)	—	—	—
’25	(13)	(10)	(11)	(13)	(47)
’24	(21)	(12)	22	(9)	(20)
’23	(26)	(21)	(25)	(7)	(78)
’22	(21)	(20)	(8)	(19)	(68)
’21	(12)	(12)	(11)	(17)	(52)
’20	(7)	(11)	(12)	(9)	(39)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(18)	(20)	—	—	—
’25	(13)	(10)	(11)	(13)	(47)
’24	(21)	(12)	22	(9)	(56)
’23	(27)	(21)	(25)	(7)	(80)
’22	(21)	(20)	(8)	(19)	(68)
’21	(12)	(12)	(11)	(17)	(52)
’20	(7)	(11)	(12)	(9)	(39)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.15)	(0.15)	—	—	—
’25	(0.12)	(0.13)	(0.12)	(0.16)	(0.53)
’24	(0.24)	(0.15)	(0.11)	(1.01)	(1.71)
’23	(0.42)	(0.42)	(0.41)	(0.02)	(1.27)
’22	(0.31)	(0.31)	(0.30)	(0.41)	(1.33)
’21	(0.57)	(0.34)	(0.35)	(0.37)	(1.60)
’20	(0.37)	(0.28)	(0.25)	(0.30)	(1.20)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	14.12	21.32	6.15	0.74	0.70	5.65	9.26	0.59	0.86	1.05	Analyst estimates 2026–2028 Powerpack
	High	31.80	33.25	26.25	8.19	7.95	30.38	18.96	18.54	5.17	3.48
People
People	Employees	31	96	169	77	60	77	105	91	64	73
	Revenue/emp, $m	0.00	0.02	0.04	0.05	0.11	0.09	0.28	0.34	0.29	0.11
Income, $m
Income, $m	Revenue	—	2	6	4	6	7	30	31	19	8
	Gross margin, %	0.00	28.28	29.62	4.07	20.81	30.29	59.80	42.14	17.43	6.93
	EBT	(48)	(70)	(82)	(114)	(51)	(91)	(87)	(89)	(132)	(65)
	EBT margin, %	0.00	(4,180.21)	(1,334.81)	(2,686.11)	(791.98)	(1,343.96)	(292.11)	(284.32)	(705.48)	(829.58)
	Net income	(48)	(69)	(133)	(161)	(51)	(91)	(87)	(88)	(132)	(65)
	Depreciation	0	0	2	25	1	1	1	1	1	0
Per share, $
Per share, $	Revenue	0.00	0.06	0.19	0.10	0.15	0.12	0.46	0.45	0.24	0.06
	Earnings	(2.25)	(2.44)	(4.03)	(3.90)	(1.20)	(1.60)	(1.33)	(1.27)	(1.71)	(0.53)
	Cash flow	(1.62)	(1.95)	(3.06)	(2.33)	(0.91)	(0.92)	(1.04)	(1.12)	(0.26)	(0.38)
	Capex	(0.01)	(0.04)	(0.04)	(0.04)	(0.01)	(0.01)	(0.01)	(0.02)	(0.46)	0.00
	Free cash flow	(1.63)	(1.99)	(3.10)	(2.37)	(0.92)	(0.92)	(1.05)	(1.14)	(0.72)	(0.39)
	Book value	7.91	8.02	6.54	1.69	0.89	3.48	3.03	2.25	2.01	0.84
	Shares, m	21	28	33	41	43	57	65	70	77	123
Valuation, ×
Valuation, ×	P/E	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	—	0.00	37.28	18.51	42.46	122.00	33.03	2.35	10.24	47.14
	P/B	—	3.12	1.33	1.12	7.31	4.18	4.97	0.47	1.23	3.58
	EV/Sales	—	0.00	19.31	1.61	35.75	95.28	26.08	(1.12)	4.75	36.92
	EV/FCF	—	(9.12)	(1.45)	(0.07)	(5.93)	(12.28)	(11.38)	0.44	(4.40)	(6.12)
Cash, $m
Cash, $m	Operating cash flow	(35)	(55)	(101)	(96)	(39)	(52)	(68)	(78)	(20)	(47)
	Capex	0	(1)	(1)	(2)	0	0	(1)	(1)	(36)	0
	Free cash flow	(35)	(56)	(102)	(98)	(39)	(52)	(68)	(80)	(56)	(47)
Balance, $m
Balance, $m	Working capital	132	187	152	61	43	182	210	98	94	68
	Total debt	—	—	30	4	11	2	2	—	—	—
	Net debt	(137)	(194)	(138)	(71)	(43)	(191)	(218)	(119)	(114)	(91)
	Shareholders’ equity	169	225	215	70	38	197	198	157	156	103
Returns, %
Returns, %	ROA	(35.59)	(32.66)	(51.14)	(86.32)	(60.34)	(56.44)	(34.36)	(39.15)	(63.23)	(34.10)
	ROIC	(94.07)	(108.19)	(68.76)	0.00	0.00	(946.13)	0.00	(159.82)	(211.41)	(387.11)
	ROE	(36.70)	(34.72)	(60.28)	(113.22)	(94.86)	(77.34)	(44.01)	(49.88)	(84.46)	(50.20)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
VECT VectivBio Holding AG	$545.5M	— (loss-making)	— (loss-making)	—	n/m	—	91.93%	0.00%	Compare
PBYI Puma Biotechnology, Inc.	$543.0M	18.2×	24.2×	+7.75% (above 0%: growing)	+33.33% (above 0%: growing)	−88.45% (below 0%: shrinking)	77.92%	13.42%	Compare
DRUG Bright Minds Biosciences Inc.	$534.7M	— (loss-making)	—	—	n/m	−124.63% (below 0%: shrinking)	0.00%	0.00%	Compare
FTH Faeth Therapeutics, Inc.	$532.3M	— (loss-making)	—	—	n/m	−174.24% (below 0%: shrinking)	0.00%	0.00%	Compare
CTMX CytomX Therapeutics, Inc.	$525.1M	— (loss-making)	— (loss-making)	−92.40% (below 0%: shrinking)	n/m	−14.50% (below 0%: shrinking)	100.00%	(1,677.08%)	Compare
CYVNY Ceryvyn Therapeutics Ltd. - Unsponsored ADR	$524.8M	— (loss-making)	— (loss-making)	−7.53% (below 0%: shrinking)	n/m	−31.52% (below 0%: shrinking)	0.00%	0.00%	Compare
ACRS Aclaris Therapeutics, Inc.	$513.7M	— (loss-making)	— (loss-making)	−8.33% (below 0%: shrinking)	n/m	−98.77% (below 0%: shrinking)	10.80%	(1,487.91%)
MNPR Monopar Therapeutics Inc.	$481.9M	— (loss-making)	—	—	n/m	−201.41% (below 0%: shrinking)	—	0.00%	Compare
ENTX Entera Bio Ltd.	$481.5M	— (loss-making)	— (loss-making)	+200.00% (above 0%: growing)	n/m	−108.86% (below 0%: shrinking)	0.00%	0.00%	Compare
Median of peers	$528.7M	—	—	+0.11%	—	−108.86%	0.00%	0.00%

All 614 Biotechnology stocks →

Aclaris Therapeutics, Inc. (ACRS) key facts

Concern: Aclaris Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $7.8 million, down 58.2% from fiscal 2024.
Aclaris Therapeutics, Inc. (ACRS) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, ACRS traded at $3.28, a market capitalization of $513.7 million.
Return on equity was −50.2% and debt-to-equity 0.00.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −5.60 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.